维普中文期刊产品整合服务
15篇 您的检索式:作者名="Tenjarla"
    题名 作者 年代 出处 被引量
1Assessment of Value and Applications of In Vitro Testing of Topical Dermatological Drug Products显示文摘Gordon L. Flynn Vinod P. Shah Srinivas N. Tenjarla Michael Corbo David DeMagistris Terry G. Feldman Thomas J. Franz Deborah R. Miran David M. Pearce Joel A. Sequeira James Swarbrick Jonas C. T. Wang Avaraham Yacobi Joel L. Zatz 1999Pharmaceutical Research1999,,9:2
2Microemulsions an overview and pharmac- eutical applications 显示文摘TENJARLA S 2009Crit Rev Ther Drug Carrier Syst2009,136,4:1
3Microemulsions as drug delivery vehicles显示文摘TENJARLA S 1996Curr Opin Colloid Interface Sci1996,1,6:1
4Preparation,characterization and evaluation of miconazole- cyclodextrin complexes for improved oral and topical delivery显示文摘Tenjarla S Puranajoti P Kasina R 1998J Pharm Sci1998,87,4:1
5Microemulsions:An overview and pharmaceutical applications显示文摘Tenjarla S 1999Critical ReviewsTMin Therapeutic Drug Carrier Systems1999,16,5:1
6Assessment of val-ue and applications of in vitro testing of topical dermatologicaldrug products显示文摘FLYNN GL SHAH VP’TENJARLA SN’ 1999Pharm Res1999,16,9:1
7Microemulsions: an overview and pharmaceutical applications 显示文摘Tenjarla S 1999Crit Rev Ther Drug Carrier Syst1999,16,5:1
8Microemulsions:an overview and pharmaceutical applications显示文摘Tenjarla S 1999Crit Rev Ther Drug Carrier Syst1999,16,5:1
9Analysis of percutaneouspermeation data II : Evaluation of the lag time method显示文摘Shah J C’Kaka I Tenjarla S 1994Int JPharm1994,109,3:1
10Release of 5-amino-salicylate from an MMX mesalamine tablet during transit through asimulated gastrointestinal tract system显示文摘Tenjarla S Romasanta V Zeijdner E 2007Adv Ther2007,24,4:1
11Microemulsions:An overview and pharmaceuticalapplications显示文摘Tenjarla S 1999Critical Reviews in Therapeutic Drug CarrierSystems1999,16,5:1
12Microemulsions:an overview and pharmaceutical applications显示文摘TENJARLA S 1999Crit Rev Ther Drug Carrier Syst1999,16,5:1
13Microemulsions:an overview and pharmaceutical applications 显示文摘TENJARLA S 1999Crit Rev Ther Drug1999,16,5:1
14Microemulsions:an overview and pharmaceutical applications显示文摘TENJARLA S 1999Crit Rev Ther Drug1999,16,5:1
15Assessment of compatibility of rhlGF-1/rhlGFBP-3 with neonatal intravenous medications显示文摘Background Recombinant human(rh)IGF-1/IGFBP-3 protein complex,administered as a continuous intravenous infusion in preterm infants,is being studied for the prevention of complications of prematurity.Methods We conducted in vitro studies to evaluate the physical and chemical compatibility of rhIGF-1/IGFBP-3 with medications routinely administered to preterm neonates.In vitro mixing of rhIGF-1/IGFBP-3 drug product with small-molecule test medications plus corresponding controls was performed.Physical compatibility was defined as no color change,precipitation,turbidity,gas evolution,no clinically relevant change in pH/osmolality or loss in medication content.Chemical compatibility of small molecules was assessed using liquid chromatography(e.g.,reverse-phase HPLC and ion chromatography),with incompatibility defined as loss of concentration of≥10%.A risk evaluation was conducted for each medication based on in vitro compatibility data and potential for chemical modification.Results In vitro physical compatibility was established for 11/19 medications:caffeine citrate,fentanyl,fluconazole,gen-tamicin,insulin,intravenous fat emulsion,midazolam,morphine sulfate,custom-mixed parenteral nutrition solution(with/without electrolytes),parenteral nutrition solution+intravenous fat emulsion,and vancomycin(dosed from a 5 mg/mL solu-tion),but not for 8/19 medications:amikacin,ampicillin,dopamine,dobutamine,furosemide,meropenem,norepinephrine,and penicillin G,largely owing to changes in pH after mixing.Small-molecule compatibility was unaffected post-mixing,with no loss of small-molecule content.For physically compatible medications,risk analyses confirmed low probability and severity of a risk event.Conclusion Co-administration of rhIGF-1/rhIGFBP-3 drug product with various medications was assessed by in vitro studies using case-by-case risk analyses to determine the suitability of the products for co-administration.Nazila Salamat-Miller Mark A.Turner Amey Bandekar Nitin Dixit Emily Jochim Barry Mangum Christopher McPherson Srini Tenjarla Sukhjeet Singh You Seok Hwang Norman Barton 2023World Journal of Pediatrics2023,19,1:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费